Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. DRUG
DRUG logo

DRUG News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

DRUG News

Drug Farm Reveals FDA Acceptance of DF-003 into Rare Disease Evidence Principles Process for Rosah Syndrome

6d agomoomoo

H.C. Wainwright Increases Target Price for Bright Minds Biosciences Inc. to $145, Up from $115

Mar 04 2026moomoo

Bright Minds Biosciences to Present at Multiple Healthcare Conferences

Feb 25 2026Newsfilter

Bright Minds Biosciences Prices 1.945M Shares at $90 for $175.05M Offering

Jan 08 2026Globenewswire

Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4

Jan 07 2026Benzinga

Bright Minds Biosciences Launches $100 Million Public Offering

Jan 07 2026Benzinga

Barclays Cuts BJ's Wholesale Price Target to $90

Jan 07 2026Benzinga

Bright Minds Reports Phase 2 BREAKTHROUGH Trial Results for BMB-101, 73.1% Seizure Reduction

Jan 06 2026Benzinga

DRUG Events

01/08 06:30
Deal Size Increased to $175M in Common Stock
The deal size was increased to $175M in common stock from $100M in common stock. Jefferies, TD Cowen, Piper Sandler and Cantor Fitzgerald acted as joint book running managers for the offering.

DRUG Monitor News

Bright Minds Biosciences stock drops after public offering announcement

Jan 08 2026

Bright Minds Biosciences Inc. Surges on BMB-101 Phase 2 Results

Jan 06 2026

DRUG Earnings Analysis

No Data

No Data

People Also Watch